Canada Pension Plan Investment Board Has $14.45 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Canada Pension Plan Investment Board trimmed its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 22.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,500 shares of the company’s stock after selling 12,500 shares during the quarter. Canada Pension Plan Investment Board owned about 0.14% of Medpace worth $14,452,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of MEDP. R Squared Ltd acquired a new position in shares of Medpace during the 4th quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace during the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its position in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock worth $38,000 after purchasing an additional 110 shares during the period. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after purchasing an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Mizuho decreased their price objective on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a report on Wednesday, April 9th. Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. TD Cowen lowered Medpace from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Leerink Partnrs upgraded Medpace to a “hold” rating in a research note on Monday, March 24th. Finally, Leerink Partners started coverage on Medpace in a report on Monday, March 24th. They issued a “market perform” rating and a $330.00 target price on the stock. Ten investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $357.50.

Medpace Trading Down 0.1 %

MEDP opened at $296.28 on Monday. The stock has a market cap of $8.96 billion, a PE ratio of 23.46, a P/E/G ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 1 year low of $272.00 and a 1 year high of $459.77. The stock’s 50 day simple moving average is $318.52 and its 200-day simple moving average is $333.25.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.